nodes	percent_of_prediction	percent_of_DWPC	metapath
Norethindrone—CYP3A4—bone cancer	0.826	1	CbGaD
Norethindrone—Embolism arterial—Epirubicin—bone cancer	0.0117	0.0833	CcSEcCtD
Norethindrone—Embolism arterial—Doxorubicin—bone cancer	0.0109	0.0771	CcSEcCtD
Norethindrone—Cerebral thrombosis—Methotrexate—bone cancer	0.00721	0.0511	CcSEcCtD
Norethindrone—Infertility—Methotrexate—bone cancer	0.00346	0.0246	CcSEcCtD
Norethindrone—Thromboembolic event—Methotrexate—bone cancer	0.00336	0.0238	CcSEcCtD
Norethindrone—Blindness—Cisplatin—bone cancer	0.00298	0.0211	CcSEcCtD
Norethindrone—Optic neuritis—Cisplatin—bone cancer	0.00268	0.019	CcSEcCtD
Norethindrone—Ethinyl Estradiol—NR1I2—bone cancer	0.00246	0.281	CrCbGaD
Norethindrone—Erythema nodosum—Epirubicin—bone cancer	0.00196	0.0139	CcSEcCtD
Norethindrone—ALB—Methotrexate—bone cancer	0.00192	0.313	CbGbCtD
Norethindrone—Tenderness—Cisplatin—bone cancer	0.00189	0.0134	CcSEcCtD
Norethindrone—Erythema nodosum—Doxorubicin—bone cancer	0.00181	0.0128	CcSEcCtD
Norethindrone—ABCB1—Cisplatin—bone cancer	0.00155	0.252	CbGbCtD
Norethindrone—Blindness—Epirubicin—bone cancer	0.00153	0.0108	CcSEcCtD
Norethindrone—Deep vein thrombosis—Methotrexate—bone cancer	0.00149	0.0105	CcSEcCtD
Norethindrone—Blindness—Doxorubicin—bone cancer	0.00141	0.01	CcSEcCtD
Norethindrone—Embolism—Methotrexate—bone cancer	0.00141	0.00998	CcSEcCtD
Norethindrone—Optic neuritis—Epirubicin—bone cancer	0.00138	0.00975	CcSEcCtD
Norethindrone—Embolism—Epirubicin—bone cancer	0.00132	0.00934	CcSEcCtD
Norethindrone—Optic neuritis—Doxorubicin—bone cancer	0.00127	0.00902	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Cisplatin—bone cancer	0.00124	0.00876	CcSEcCtD
Norethindrone—Embolism—Doxorubicin—bone cancer	0.00122	0.00865	CcSEcCtD
Norethindrone—Thrombosis—Epirubicin—bone cancer	0.0012	0.00847	CcSEcCtD
Norethindrone—Dermatitis atopic—Epirubicin—bone cancer	0.00114	0.0081	CcSEcCtD
Norethindrone—Vaginal haemorrhage—Epirubicin—bone cancer	0.00114	0.0081	CcSEcCtD
Norethindrone—Thrombosis—Doxorubicin—bone cancer	0.00111	0.00784	CcSEcCtD
Norethindrone—Breast disorder—Cisplatin—bone cancer	0.00108	0.00766	CcSEcCtD
Norethindrone—Vaginal haemorrhage—Doxorubicin—bone cancer	0.00106	0.0075	CcSEcCtD
Norethindrone—Dermatitis atopic—Doxorubicin—bone cancer	0.00106	0.0075	CcSEcCtD
Norethindrone—Allylestrenol—CYP3A4—bone cancer	0.00105	0.12	CrCbGaD
Norethindrone—ABCB1—Doxorubicin—bone cancer	0.00104	0.169	CbGbCtD
Norethindrone—ABCB1—Methotrexate—bone cancer	0.00101	0.164	CbGbCtD
Norethindrone—Neoplasm malignant—Epirubicin—bone cancer	0.000991	0.00702	CcSEcCtD
Norethindrone—CYP3A7—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000986	0.0554	CbGpPWpGaD
Norethindrone—Breast pain—Epirubicin—bone cancer	0.00097	0.00688	CcSEcCtD
Norethindrone—Amenorrhoea—Epirubicin—bone cancer	0.000963	0.00683	CcSEcCtD
Norethindrone—Jaundice cholestatic—Epirubicin—bone cancer	0.000963	0.00683	CcSEcCtD
Norethindrone—Neoplasm malignant—Doxorubicin—bone cancer	0.000917	0.0065	CcSEcCtD
Norethindrone—Acute coronary syndrome—Cisplatin—bone cancer	0.000909	0.00644	CcSEcCtD
Norethindrone—Renal failure—Cisplatin—bone cancer	0.000906	0.00642	CcSEcCtD
Norethindrone—Pulmonary embolism—Methotrexate—bone cancer	0.000904	0.00641	CcSEcCtD
Norethindrone—Myocardial infarction—Cisplatin—bone cancer	0.000904	0.0064	CcSEcCtD
Norethindrone—Breast pain—Doxorubicin—bone cancer	0.000897	0.00636	CcSEcCtD
Norethindrone—Jaundice cholestatic—Doxorubicin—bone cancer	0.000891	0.00632	CcSEcCtD
Norethindrone—Amenorrhoea—Doxorubicin—bone cancer	0.000891	0.00632	CcSEcCtD
Norethindrone—Hepatobiliary disease—Cisplatin—bone cancer	0.000872	0.00618	CcSEcCtD
Norethindrone—PGR—Nuclear Receptors—NR1I2—bone cancer	0.000856	0.0481	CbGpPWpGaD
Norethindrone—Pulmonary embolism—Epirubicin—bone cancer	0.000846	0.006	CcSEcCtD
Norethindrone—Cortisone acetate—CYP3A4—bone cancer	0.000842	0.096	CrCbGaD
Norethindrone—Etonogestrel—CYP3A4—bone cancer	0.000818	0.0932	CrCbGaD
Norethindrone—Connective tissue disorder—Cisplatin—bone cancer	0.000813	0.00576	CcSEcCtD
Norethindrone—Pulmonary embolism—Doxorubicin—bone cancer	0.000783	0.00555	CcSEcCtD
Norethindrone—Thrombophlebitis—Methotrexate—bone cancer	0.000758	0.00537	CcSEcCtD
Norethindrone—Photosensitivity—Methotrexate—bone cancer	0.000748	0.0053	CcSEcCtD
Norethindrone—Immune system disorder—Cisplatin—bone cancer	0.000747	0.0053	CcSEcCtD
Norethindrone—Alopecia—Cisplatin—bone cancer	0.000731	0.00518	CcSEcCtD
Norethindrone—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000712	0.0401	CbGpPWpGaD
Norethindrone—Flatulence—Cisplatin—bone cancer	0.00071	0.00503	CcSEcCtD
Norethindrone—Thrombophlebitis—Epirubicin—bone cancer	0.00071	0.00503	CcSEcCtD
Norethindrone—Photosensitivity—Epirubicin—bone cancer	0.0007	0.00496	CcSEcCtD
Norethindrone—Drospirenone—PTGS2—bone cancer	0.000694	0.0791	CrCbGaD
Norethindrone—Anaphylactoid reaction—Methotrexate—bone cancer	0.000678	0.00481	CcSEcCtD
Norethindrone—PGR—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.000676	0.038	CbGpPWpGaD
Norethindrone—Thrombophlebitis—Doxorubicin—bone cancer	0.000657	0.00465	CcSEcCtD
Norethindrone—Photosensitivity—Doxorubicin—bone cancer	0.000647	0.00459	CcSEcCtD
Norethindrone—Renal impairment—Epirubicin—bone cancer	0.000645	0.00458	CcSEcCtD
Norethindrone—Purpura—Epirubicin—bone cancer	0.000637	0.00452	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Epirubicin—bone cancer	0.000635	0.0045	CcSEcCtD
Norethindrone—Convulsion—Cisplatin—bone cancer	0.000624	0.00442	CcSEcCtD
Norethindrone—CYP3A4—Doxorubicin—bone cancer	0.000622	0.101	CbGbCtD
Norethindrone—Mood swings—Methotrexate—bone cancer	0.000622	0.00441	CcSEcCtD
Norethindrone—Pain in extremity—Epirubicin—bone cancer	0.000614	0.00435	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000609	0.00432	CcSEcCtD
Norethindrone—Migraine—Epirubicin—bone cancer	0.000605	0.00429	CcSEcCtD
Norethindrone—Affect lability—Epirubicin—bone cancer	0.000605	0.00429	CcSEcCtD
Norethindrone—Renal impairment—Doxorubicin—bone cancer	0.000597	0.00423	CcSEcCtD
Norethindrone—Breast disorder—Methotrexate—bone cancer	0.000593	0.0042	CcSEcCtD
Norethindrone—Purpura—Doxorubicin—bone cancer	0.00059	0.00418	CcSEcCtD
Norethindrone—Oedema—Cisplatin—bone cancer	0.000588	0.00417	CcSEcCtD
Norethindrone—Anaphylactic shock—Cisplatin—bone cancer	0.000588	0.00417	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Doxorubicin—bone cancer	0.000587	0.00416	CcSEcCtD
Norethindrone—Mood swings—Epirubicin—bone cancer	0.000582	0.00412	CcSEcCtD
Norethindrone—Levonorgestrel—CYP3A4—bone cancer	0.000578	0.066	CrCbGaD
Norethindrone—Skin disorder—Cisplatin—bone cancer	0.000571	0.00405	CcSEcCtD
Norethindrone—Pain in extremity—Doxorubicin—bone cancer	0.000568	0.00403	CcSEcCtD
Norethindrone—Migraine—Doxorubicin—bone cancer	0.000559	0.00397	CcSEcCtD
Norethindrone—Affect lability—Doxorubicin—bone cancer	0.000559	0.00397	CcSEcCtD
Norethindrone—Breast disorder—Epirubicin—bone cancer	0.000555	0.00393	CcSEcCtD
Norethindrone—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000551	0.031	CbGpPWpGaD
Norethindrone—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00054	0.0304	CbGpPWpGaD
Norethindrone—Mood swings—Doxorubicin—bone cancer	0.000538	0.00382	CcSEcCtD
Norethindrone—Abdominal distension—Epirubicin—bone cancer	0.000534	0.00379	CcSEcCtD
Norethindrone—Danazol—CYP3A4—bone cancer	0.000527	0.0601	CrCbGaD
Norethindrone—Photosensitivity reaction—Methotrexate—bone cancer	0.000518	0.00367	CcSEcCtD
Norethindrone—Breast disorder—Doxorubicin—bone cancer	0.000514	0.00364	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Cisplatin—bone cancer	0.000508	0.0036	CcSEcCtD
Norethindrone—Drowsiness—Methotrexate—bone cancer	0.000506	0.00359	CcSEcCtD
Norethindrone—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000506	0.0284	CbGpPWpGaD
Norethindrone—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.000505	0.0284	CbGpPWpGaD
Norethindrone—Depression—Methotrexate—bone cancer	0.000504	0.00358	CcSEcCtD
Norethindrone—Renal failure—Methotrexate—bone cancer	0.000497	0.00352	CcSEcCtD
Norethindrone—Abdominal distension—Doxorubicin—bone cancer	0.000495	0.00351	CcSEcCtD
Norethindrone—ALB—Folate Metabolism—FOLR1—bone cancer	0.00049	0.0276	CbGpPWpGaD
Norethindrone—Ethinyl Estradiol—CYP3A4—bone cancer	0.000487	0.0556	CrCbGaD
Norethindrone—Photosensitivity reaction—Epirubicin—bone cancer	0.000485	0.00344	CcSEcCtD
Norethindrone—Weight increased—Epirubicin—bone cancer	0.000483	0.00342	CcSEcCtD
Norethindrone—Hepatobiliary disease—Methotrexate—bone cancer	0.000478	0.00339	CcSEcCtD
Norethindrone—CYP3A7—Xenobiotics—CYP3A4—bone cancer	0.000476	0.0268	CbGpPWpGaD
Norethindrone—Drowsiness—Epirubicin—bone cancer	0.000473	0.00336	CcSEcCtD
Norethindrone—Renal failure—Epirubicin—bone cancer	0.000465	0.0033	CcSEcCtD
Norethindrone—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.000457	0.0257	CbGpPWpGaD
Norethindrone—Haemoglobin—Methotrexate—bone cancer	0.000456	0.00324	CcSEcCtD
Norethindrone—Hepatitis—Methotrexate—bone cancer	0.000454	0.00322	CcSEcCtD
Norethindrone—Haemorrhage—Methotrexate—bone cancer	0.000454	0.00322	CcSEcCtD
Norethindrone—Photosensitivity reaction—Doxorubicin—bone cancer	0.000448	0.00318	CcSEcCtD
Norethindrone—Hepatobiliary disease—Epirubicin—bone cancer	0.000448	0.00317	CcSEcCtD
Norethindrone—Weight increased—Doxorubicin—bone cancer	0.000447	0.00317	CcSEcCtD
Norethindrone—Methyltestosterone—CYP3A4—bone cancer	0.000445	0.0508	CrCbGaD
Norethindrone—Drowsiness—Doxorubicin—bone cancer	0.000438	0.0031	CcSEcCtD
Norethindrone—Hypersensitivity—Cisplatin—bone cancer	0.000433	0.00307	CcSEcCtD
Norethindrone—Renal failure—Doxorubicin—bone cancer	0.000431	0.00305	CcSEcCtD
Norethindrone—Erythema multiforme—Methotrexate—bone cancer	0.000429	0.00304	CcSEcCtD
Norethindrone—Haemoglobin—Epirubicin—bone cancer	0.000427	0.00303	CcSEcCtD
Norethindrone—Haemorrhage—Epirubicin—bone cancer	0.000425	0.00301	CcSEcCtD
Norethindrone—Hepatitis—Epirubicin—bone cancer	0.000425	0.00301	CcSEcCtD
Norethindrone—CYP3A7—Metapathway biotransformation—CYP4V2—bone cancer	0.000424	0.0239	CbGpPWpGaD
Norethindrone—Asthenia—Cisplatin—bone cancer	0.000422	0.00299	CcSEcCtD
Norethindrone—Connective tissue disorder—Epirubicin—bone cancer	0.000418	0.00296	CcSEcCtD
Norethindrone—Hepatobiliary disease—Doxorubicin—bone cancer	0.000414	0.00294	CcSEcCtD
Norethindrone—Immune system disorder—Methotrexate—bone cancer	0.00041	0.00291	CcSEcCtD
Norethindrone—Erythema multiforme—Epirubicin—bone cancer	0.000402	0.00285	CcSEcCtD
Norethindrone—Alopecia—Methotrexate—bone cancer	0.000401	0.00284	CcSEcCtD
Norethindrone—Mental disorder—Methotrexate—bone cancer	0.000398	0.00282	CcSEcCtD
Norethindrone—Haemoglobin—Doxorubicin—bone cancer	0.000395	0.0028	CcSEcCtD
Norethindrone—Hepatitis—Doxorubicin—bone cancer	0.000393	0.00279	CcSEcCtD
Norethindrone—Haemorrhage—Doxorubicin—bone cancer	0.000393	0.00279	CcSEcCtD
Norethindrone—Connective tissue disorder—Doxorubicin—bone cancer	0.000386	0.00274	CcSEcCtD
Norethindrone—Immune system disorder—Epirubicin—bone cancer	0.000384	0.00272	CcSEcCtD
Norethindrone—Alopecia—Epirubicin—bone cancer	0.000376	0.00266	CcSEcCtD
Norethindrone—Vomiting—Cisplatin—bone cancer	0.000374	0.00265	CcSEcCtD
Norethindrone—Mental disorder—Epirubicin—bone cancer	0.000372	0.00264	CcSEcCtD
Norethindrone—Erythema multiforme—Doxorubicin—bone cancer	0.000372	0.00264	CcSEcCtD
Norethindrone—Rash—Cisplatin—bone cancer	0.000371	0.00263	CcSEcCtD
Norethindrone—Dermatitis—Cisplatin—bone cancer	0.00037	0.00263	CcSEcCtD
Norethindrone—Flatulence—Epirubicin—bone cancer	0.000365	0.00258	CcSEcCtD
Norethindrone—Tension—Epirubicin—bone cancer	0.000363	0.00257	CcSEcCtD
Norethindrone—Nervousness—Epirubicin—bone cancer	0.000359	0.00255	CcSEcCtD
Norethindrone—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000358	0.0202	CbGpPWpGaD
Norethindrone—PGR—Ovarian Infertility Genes—CDK4—bone cancer	0.000356	0.02	CbGpPWpGaD
Norethindrone—Immune system disorder—Doxorubicin—bone cancer	0.000355	0.00252	CcSEcCtD
Norethindrone—Nausea—Cisplatin—bone cancer	0.000349	0.00248	CcSEcCtD
Norethindrone—Alopecia—Doxorubicin—bone cancer	0.000347	0.00246	CcSEcCtD
Norethindrone—PGR—Generic Transcription Pathway—ZNF77—bone cancer	0.000345	0.0194	CbGpPWpGaD
Norethindrone—Mental disorder—Doxorubicin—bone cancer	0.000344	0.00244	CcSEcCtD
Norethindrone—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.000344	0.0193	CbGpPWpGaD
Norethindrone—Convulsion—Methotrexate—bone cancer	0.000342	0.00243	CcSEcCtD
Norethindrone—Flatulence—Doxorubicin—bone cancer	0.000337	0.00239	CcSEcCtD
Norethindrone—Tension—Doxorubicin—bone cancer	0.000336	0.00238	CcSEcCtD
Norethindrone—Hydrocortisone—CYP3A4—bone cancer	0.000335	0.0382	CrCbGaD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000334	0.00237	CcSEcCtD
Norethindrone—Nervousness—Doxorubicin—bone cancer	0.000332	0.00236	CcSEcCtD
Norethindrone—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000331	0.0186	CbGpPWpGaD
Norethindrone—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.000331	0.0186	CbGpPWpGaD
Norethindrone—Anaphylactic shock—Methotrexate—bone cancer	0.000323	0.00229	CcSEcCtD
Norethindrone—Convulsion—Epirubicin—bone cancer	0.000321	0.00227	CcSEcCtD
Norethindrone—Skin disorder—Methotrexate—bone cancer	0.000313	0.00222	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000313	0.00222	CcSEcCtD
Norethindrone—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000312	0.0175	CbGpPWpGaD
Norethindrone—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000307	0.0172	CbGpPWpGaD
Norethindrone—Oedema—Epirubicin—bone cancer	0.000302	0.00214	CcSEcCtD
Norethindrone—Anaphylactic shock—Epirubicin—bone cancer	0.000302	0.00214	CcSEcCtD
Norethindrone—Convulsion—Doxorubicin—bone cancer	0.000297	0.0021	CcSEcCtD
Norethindrone—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000295	0.0166	CbGpPWpGaD
Norethindrone—Skin disorder—Epirubicin—bone cancer	0.000293	0.00208	CcSEcCtD
Norethindrone—Insomnia—Methotrexate—bone cancer	0.000292	0.00207	CcSEcCtD
Norethindrone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00029	0.0163	CbGpPWpGaD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000289	0.00205	CcSEcCtD
Norethindrone—Somnolence—Methotrexate—bone cancer	0.000287	0.00203	CcSEcCtD
Norethindrone—Dyspepsia—Methotrexate—bone cancer	0.000284	0.00201	CcSEcCtD
Norethindrone—Anaphylactic shock—Doxorubicin—bone cancer	0.000279	0.00198	CcSEcCtD
Norethindrone—Oedema—Doxorubicin—bone cancer	0.000279	0.00198	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Methotrexate—bone cancer	0.000279	0.00197	CcSEcCtD
Norethindrone—Fatigue—Methotrexate—bone cancer	0.000278	0.00197	CcSEcCtD
Norethindrone—Progesterone—CYP3A4—bone cancer	0.000273	0.0311	CrCbGaD
Norethindrone—Insomnia—Epirubicin—bone cancer	0.000273	0.00194	CcSEcCtD
Norethindrone—Skin disorder—Doxorubicin—bone cancer	0.000271	0.00192	CcSEcCtD
Norethindrone—Somnolence—Epirubicin—bone cancer	0.000268	0.0019	CcSEcCtD
Norethindrone—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000266	0.015	CbGpPWpGaD
Norethindrone—Dyspepsia—Epirubicin—bone cancer	0.000266	0.00188	CcSEcCtD
Norethindrone—Gastrointestinal pain—Methotrexate—bone cancer	0.000264	0.00187	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Epirubicin—bone cancer	0.000261	0.00185	CcSEcCtD
Norethindrone—Fatigue—Epirubicin—bone cancer	0.00026	0.00185	CcSEcCtD
Norethindrone—Testosterone—CYP3A4—bone cancer	0.000258	0.0294	CrCbGaD
Norethindrone—Urticaria—Methotrexate—bone cancer	0.000256	0.00182	CcSEcCtD
Norethindrone—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000256	0.0144	CbGpPWpGaD
Norethindrone—Abdominal pain—Methotrexate—bone cancer	0.000255	0.00181	CcSEcCtD
Norethindrone—Insomnia—Doxorubicin—bone cancer	0.000253	0.00179	CcSEcCtD
Norethindrone—Somnolence—Doxorubicin—bone cancer	0.000248	0.00176	CcSEcCtD
Norethindrone—Gastrointestinal pain—Epirubicin—bone cancer	0.000247	0.00175	CcSEcCtD
Norethindrone—Dyspepsia—Doxorubicin—bone cancer	0.000246	0.00174	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000241	0.00171	CcSEcCtD
Norethindrone—Fatigue—Doxorubicin—bone cancer	0.000241	0.00171	CcSEcCtD
Norethindrone—Urticaria—Epirubicin—bone cancer	0.00024	0.0017	CcSEcCtD
Norethindrone—Abdominal pain—Epirubicin—bone cancer	0.000239	0.00169	CcSEcCtD
Norethindrone—Hypersensitivity—Methotrexate—bone cancer	0.000238	0.00168	CcSEcCtD
Norethindrone—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000237	0.0133	CbGpPWpGaD
Norethindrone—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000236	0.0133	CbGpPWpGaD
Norethindrone—Asthenia—Methotrexate—bone cancer	0.000231	0.00164	CcSEcCtD
Norethindrone—Gastrointestinal pain—Doxorubicin—bone cancer	0.000228	0.00162	CcSEcCtD
Norethindrone—Pruritus—Methotrexate—bone cancer	0.000228	0.00162	CcSEcCtD
Norethindrone—Hypersensitivity—Epirubicin—bone cancer	0.000222	0.00158	CcSEcCtD
Norethindrone—Urticaria—Doxorubicin—bone cancer	0.000222	0.00157	CcSEcCtD
Norethindrone—Abdominal pain—Doxorubicin—bone cancer	0.000221	0.00157	CcSEcCtD
Norethindrone—Asthenia—Epirubicin—bone cancer	0.000217	0.00154	CcSEcCtD
Norethindrone—Pruritus—Epirubicin—bone cancer	0.000214	0.00151	CcSEcCtD
Norethindrone—Dizziness—Methotrexate—bone cancer	0.000213	0.00151	CcSEcCtD
Norethindrone—Hypersensitivity—Doxorubicin—bone cancer	0.000206	0.00146	CcSEcCtD
Norethindrone—Vomiting—Methotrexate—bone cancer	0.000205	0.00145	CcSEcCtD
Norethindrone—Rash—Methotrexate—bone cancer	0.000203	0.00144	CcSEcCtD
Norethindrone—Dermatitis—Methotrexate—bone cancer	0.000203	0.00144	CcSEcCtD
Norethindrone—Headache—Methotrexate—bone cancer	0.000202	0.00143	CcSEcCtD
Norethindrone—ALB—Binding and Uptake of Ligands by Scavenger Receptors—SPARC—bone cancer	0.000201	0.0113	CbGpPWpGaD
Norethindrone—Asthenia—Doxorubicin—bone cancer	0.0002	0.00142	CcSEcCtD
Norethindrone—Dizziness—Epirubicin—bone cancer	0.0002	0.00142	CcSEcCtD
Norethindrone—Pruritus—Doxorubicin—bone cancer	0.000198	0.0014	CcSEcCtD
Norethindrone—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000197	0.0111	CbGpPWpGaD
Norethindrone—CYP3A7—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000195	0.011	CbGpPWpGaD
Norethindrone—Vomiting—Epirubicin—bone cancer	0.000192	0.00136	CcSEcCtD
Norethindrone—Nausea—Methotrexate—bone cancer	0.000192	0.00136	CcSEcCtD
Norethindrone—Rash—Epirubicin—bone cancer	0.00019	0.00135	CcSEcCtD
Norethindrone—Dermatitis—Epirubicin—bone cancer	0.00019	0.00135	CcSEcCtD
Norethindrone—Headache—Epirubicin—bone cancer	0.000189	0.00134	CcSEcCtD
Norethindrone—Dizziness—Doxorubicin—bone cancer	0.000185	0.00131	CcSEcCtD
Norethindrone—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000182	0.0103	CbGpPWpGaD
Norethindrone—Nausea—Epirubicin—bone cancer	0.000179	0.00127	CcSEcCtD
Norethindrone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000179	0.0101	CbGpPWpGaD
Norethindrone—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000178	0.01	CbGpPWpGaD
Norethindrone—Vomiting—Doxorubicin—bone cancer	0.000178	0.00126	CcSEcCtD
Norethindrone—Rash—Doxorubicin—bone cancer	0.000176	0.00125	CcSEcCtD
Norethindrone—Dermatitis—Doxorubicin—bone cancer	0.000176	0.00125	CcSEcCtD
Norethindrone—Headache—Doxorubicin—bone cancer	0.000175	0.00124	CcSEcCtD
Norethindrone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00017	0.00955	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—ZNF77—bone cancer	0.000166	0.00935	CbGpPWpGaD
Norethindrone—Nausea—Doxorubicin—bone cancer	0.000166	0.00118	CcSEcCtD
Norethindrone—CYP3A7—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00016	0.00901	CbGpPWpGaD
Norethindrone—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000143	0.00803	CbGpPWpGaD
Norethindrone—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000143	0.00802	CbGpPWpGaD
Norethindrone—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000141	0.00793	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—DHFR—bone cancer	0.000134	0.00756	CbGpPWpGaD
Norethindrone—PGR—Validated nuclear estrogen receptor alpha network—JUN—bone cancer	0.000132	0.0074	CbGpPWpGaD
Norethindrone—ALB—Platelet degranulation—SPARC—bone cancer	0.000118	0.00663	CbGpPWpGaD
Norethindrone—PGR—Generic Transcription Pathway—NR1I2—bone cancer	0.000117	0.00657	CbGpPWpGaD
Norethindrone—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000116	0.00651	CbGpPWpGaD
Norethindrone—ALB—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.000112	0.00631	CbGpPWpGaD
Norethindrone—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00011	0.00621	CbGpPWpGaD
Norethindrone—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000109	0.00613	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—KIT—bone cancer	9.62e-05	0.00541	CbGpPWpGaD
Norethindrone—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	8.95e-05	0.00503	CbGpPWpGaD
Norethindrone—CYP3A7—Biological oxidations—CYP3A4—bone cancer	8.5e-05	0.00478	CbGpPWpGaD
Norethindrone—CYP3A7—Metapathway biotransformation—CYP3A4—bone cancer	8.39e-05	0.00472	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—FUS—bone cancer	8.11e-05	0.00456	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—MDM2—bone cancer	7.58e-05	0.00426	CbGpPWpGaD
Norethindrone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	7.39e-05	0.00416	CbGpPWpGaD
Norethindrone—CYP3A7—Biological oxidations—GSTP1—bone cancer	7.27e-05	0.00409	CbGpPWpGaD
Norethindrone—CYP3A7—Metapathway biotransformation—GSTP1—bone cancer	7.17e-05	0.00404	CbGpPWpGaD
Norethindrone—CYP3A5—Biological oxidations—CYP3A4—bone cancer	6.15e-05	0.00346	CbGpPWpGaD
Norethindrone—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	6.06e-05	0.00341	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	6.05e-05	0.0034	CbGpPWpGaD
Norethindrone—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	5.66e-05	0.00318	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—NR1I2—bone cancer	5.62e-05	0.00316	CbGpPWpGaD
Norethindrone—CYP3A5—Biological oxidations—GSTP1—bone cancer	5.26e-05	0.00296	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	5.22e-05	0.00294	CbGpPWpGaD
Norethindrone—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	5.19e-05	0.00292	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—EGFR—bone cancer	5.18e-05	0.00291	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	5.14e-05	0.00289	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—NDUFA12—bone cancer	5.1e-05	0.00287	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	4.78e-05	0.00269	CbGpPWpGaD
Norethindrone—CYP2C19—Biological oxidations—CYP3A4—bone cancer	4.75e-05	0.00267	CbGpPWpGaD
Norethindrone—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	4.69e-05	0.00264	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	4.68e-05	0.00264	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	4.33e-05	0.00244	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	4.27e-05	0.0024	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—NT5C3A—bone cancer	4.22e-05	0.00238	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—GRM4—bone cancer	4.22e-05	0.00237	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—RGS1—bone cancer	4.22e-05	0.00237	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	4.21e-05	0.00237	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—EIF2S1—bone cancer	4.15e-05	0.00234	CbGpPWpGaD
Norethindrone—CYP2C19—Biological oxidations—GSTP1—bone cancer	4.06e-05	0.00229	CbGpPWpGaD
Norethindrone—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	4.06e-05	0.00228	CbGpPWpGaD
Norethindrone—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	4.01e-05	0.00226	CbGpPWpGaD
Norethindrone—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	4.01e-05	0.00226	CbGpPWpGaD
Norethindrone—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	3.99e-05	0.00224	CbGpPWpGaD
Norethindrone—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	3.77e-05	0.00212	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—NDUFA12—bone cancer	3.68e-05	0.00207	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—GRM1—bone cancer	3.66e-05	0.00206	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—EZH2—bone cancer	3.61e-05	0.00203	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	3.57e-05	0.00201	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	3.56e-05	0.002	CbGpPWpGaD
Norethindrone—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	3.5e-05	0.00197	CbGpPWpGaD
Norethindrone—ALB—Metabolism—NDUFA12—bone cancer	3.17e-05	0.00179	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	3.07e-05	0.00173	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—NT5C3A—bone cancer	3.05e-05	0.00172	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—TP53—bone cancer	3e-05	0.00169	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—NDUFA12—bone cancer	2.85e-05	0.0016	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—NDUFA12—bone cancer	2.78e-05	0.00156	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—SPARC—bone cancer	2.69e-05	0.00152	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	2.64e-05	0.00149	CbGpPWpGaD
Norethindrone—ALB—Metabolism—NT5C3A—bone cancer	2.63e-05	0.00148	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—SMO—bone cancer	2.58e-05	0.00145	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—GNA11—bone cancer	2.46e-05	0.00139	CbGpPWpGaD
Norethindrone—CYP3A4—Biological oxidations—GSTP1—bone cancer	2.44e-05	0.00138	CbGpPWpGaD
Norethindrone—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	2.41e-05	0.00136	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—NT5C3A—bone cancer	2.36e-05	0.00133	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—GNA11—bone cancer	2.36e-05	0.00133	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—NT5C3A—bone cancer	2.3e-05	0.0013	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—IL3—bone cancer	2.23e-05	0.00126	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—ATF1—bone cancer	2.19e-05	0.00123	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—IL3—bone cancer	2.14e-05	0.0012	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	1.96e-05	0.0011	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	1.89e-05	0.00106	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—ENO2—bone cancer	1.85e-05	0.00104	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—TGFBR2—bone cancer	1.83e-05	0.00103	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—IGF1R—bone cancer	1.72e-05	0.000967	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—DHFR—bone cancer	1.72e-05	0.000966	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—NDUFA12—bone cancer	1.71e-05	0.000964	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	1.7e-05	0.000959	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—GNA11—bone cancer	1.6e-05	0.000902	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—PLAU—bone cancer	1.46e-05	0.000824	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—CYP3A4—bone cancer	1.45e-05	0.000818	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—NT5C3A—bone cancer	1.42e-05	0.000799	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.34e-05	0.000754	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—ENO2—bone cancer	1.34e-05	0.000752	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—KIT—bone cancer	1.25e-05	0.000701	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—GSTP1—bone cancer	1.24e-05	0.0007	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—DHFR—bone cancer	1.24e-05	0.000698	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—BRAF—bone cancer	1.17e-05	0.000659	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—GNA11—bone cancer	1.16e-05	0.000652	CbGpPWpGaD
Norethindrone—ALB—Metabolism—ENO2—bone cancer	1.15e-05	0.000648	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.12e-05	0.000633	CbGpPWpGaD
Norethindrone—ALB—Metabolism—DHFR—bone cancer	1.07e-05	0.000601	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—CYP3A4—bone cancer	1.05e-05	0.000591	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—ENO2—bone cancer	1.03e-05	0.000582	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—ENO2—bone cancer	1.01e-05	0.000568	CbGpPWpGaD
Norethindrone—ALB—Metabolism—GNA11—bone cancer	9.99e-06	0.000562	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—MDM2—bone cancer	9.82e-06	0.000552	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—DHFR—bone cancer	9.59e-06	0.00054	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—DHFR—bone cancer	9.36e-06	0.000527	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CYP3A4—bone cancer	9.05e-06	0.000509	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.01e-06	0.000507	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—GSTP1—bone cancer	8.99e-06	0.000506	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—GNA11—bone cancer	8.97e-06	0.000504	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—GNA11—bone cancer	8.75e-06	0.000492	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—JUN—bone cancer	8.53e-06	0.00048	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—MMP9—bone cancer	8.3e-06	0.000467	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CYP3A4—bone cancer	8.13e-06	0.000457	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	8.09e-06	0.000455	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CYP3A4—bone cancer	7.93e-06	0.000446	CbGpPWpGaD
Norethindrone—ALB—Metabolism—GSTP1—bone cancer	7.74e-06	0.000436	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—GSTP1—bone cancer	6.95e-06	0.000391	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—GSTP1—bone cancer	6.78e-06	0.000382	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—EGFR—bone cancer	6.71e-06	0.000377	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PTGS2—bone cancer	6.44e-06	0.000363	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—ENO2—bone cancer	6.22e-06	0.00035	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—TP53—bone cancer	5.89e-06	0.000331	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—DHFR—bone cancer	5.77e-06	0.000324	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—TP53—bone cancer	5.63e-06	0.000317	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GNA11—bone cancer	5.39e-06	0.000303	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PTGS2—bone cancer	4.66e-06	0.000262	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GSTP1—bone cancer	4.18e-06	0.000235	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PTGS2—bone cancer	4.01e-06	0.000226	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PTGS2—bone cancer	3.6e-06	0.000203	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PTGS2—bone cancer	3.51e-06	0.000198	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PTGS2—bone cancer	2.17e-06	0.000122	CbGpPWpGaD
